Dr. Reddy’s to acquire Slayback’s eyedrop rights
The Hindu
HYDERABAD Pharma major Dr. Reddy’s Laboratories has entered into a licensing agreement to obtain r
Pharma major Dr. Reddy’s Laboratories has entered into a licensing agreement to obtain rights to New Jersey-based Slayback Pharma’s Brimonidine Tartrate Ophthalmic Solution 0.025%.
Slayback Pharma is the first to file an ANDA (abbreviated new drug application) for the private label equivalent for Lumify with the U.S. Food and Drug Administration (USFDA) under Paragraph IV certification.
The ANDA is currently under USFDA review and covers Brimonidine Tartrate Ophthalmic Solution 0.025% in 2.5 ml and 7.5 ml fill volumes, Dr. Reddy’s said in a release.
A trademark of Bausch & Lomb, Lumify is an over-the-counter (OTC) eyedrop that can be used to relieve redness of the eye due to minor eye irritations. The agreement also provides Dr. Reddy’s exclusive rights to the product outside the U.S.
“We are pleased to license this important OTC ophthalmic product for the U.S. market. It complements the company’s growing OTC product portfolio in eyecare category,” said Marc Kikuchi, CEO, North America Generics of Dr. Reddy’s.
CEO and founder of Slayback Ajay Singh, who was previously with Dr. Reddy’s as vice-president of strategy, portfolio and business development for the North American Generics Division, said, “Slayback is proud to develop this first-to-file ANDA for Lumify, a significant OTC product in the eye redness reliever category, that continues to highlight the R&D capability of the company.”
Slayback is focused on complex generic and specialty pharmaceutical products has operations in the U.S., India and Europe, according to the company.
Adani Group plans a ₹1.5 lakh crore investment in Kutch, focusing on renewable energy, ports, and logistics over five years.
Mukesh Ambani announces ₹7 lakh crore investment in Gujarat, emphasizing clean energy, AI, and support for Olympic ambitions.
India mandates selfies and 'penny drop' for crypto KYC, discouraging ICOs and ensuring strict anti-money laundering measures.
Mukesh Ambani announces ₹7 lakh crore investment in Gujarat, emphasizing clean energy, AI, and support for Olympic ambitions.
The All India Cashew Association calls for urgent action against illegal cashew imports threatening India's domestic processing industry.
Moody’s upgrades Shriram Finance’s outlook to positive, citing strategic benefits from MUFG Bank's upcoming investment and improved financial stability.
India's rice exports soar to near record levels in 2025, driven by lifted curbs and increased global demand.
Dr. Reddy's responds to U.S. FDA queries regarding its Hyderabad biologics facility following a recent inspection.
Techno Paints plans a ₹500 crore IPO in FY27, featuring Sachin Tendulkar as brand ambassador to boost growth.
India's shift from Russian oil imports will have limited fiscal impact due to low global prices and reduced discounts.
The latest Household Consumption Expenditure Survey (HCES) by MoS&PI reveals a transformative shift in India’s economic landscape. For the first time in over a decade, granular data on Monthly Per Capita Expenditure (MPCE) highlights a significant decline in the proportional share of food spending—a classic validation of Engel’s Law as real incomes rise. Between 1999 and 2024, both rural and urban consumption pivoted away from staple-heavy diets toward protein-rich foods, health, education, and conveyance. As Indian households move beyond subsistence, these shifting Indian household spending patterns offer vital insights for social sector policy, poverty estimation, and the lived realities of an expanding middle-income population.
Investors shifted to Gold ETFs in December 2025, with record inflows amid macro uncertainty and declining equity returns.
Aurobindo Pharma's subsidiary receives Health Canada NOC for Dyrupeg, confirming its pegylated filgrastim biosimilar's safety and efficacy.